实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (5): 731-734.doi: 10.3969/j.issn.1672-5069.2025.05.023

• 肝硬化 • 上一篇    下一篇

内镜下组织胶注射治疗乙型肝炎肝硬化食管胃底静脉曲张破裂出血患者疗效分析*

朱颖静, 吴洁, 田鑫越, 田巍巍   

  1. 226500 江苏省南通市 南通大学附属如皋医院/如皋市人民医院消化内科
  • 收稿日期:2024-01-08 出版日期:2025-09-10 发布日期:2025-09-19
  • 通讯作者: 田巍巍,E-mail:zyj845022724@163.com
  • 作者简介:朱颖静,女,30岁,大学本科,住院医师。E-mail:zyj845022724@163.com
  • 基金资助:
    *江苏省研究生科研与实践创新计划项目(编号:SJCX21-1650)

Endoscopic tissue glue injection and esophageal variceal ligation in treatment of patients with hepatitis B-induced liver cirrhosis and esophageal and gastric varices bleeding

Zhu Yingjing, Wu Jie, Tian Xinyue, et al   

  1. Department of Gastroenterology, Rugao People's Hospital, Affiliated to Nantong University, Nantong 226500, Jiangsu Province, China
  • Received:2024-01-08 Online:2025-09-10 Published:2025-09-19

摘要: 目的 探讨内镜下组织胶注射与内镜下曲张静脉套扎术(EVL)治疗乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血(EGVB)患者的临床疗效,为临床诊疗提供依据。方法 2019年9月~2022年12月我院诊治的乙型肝炎肝硬化并发EGVB患者68例,被随机分为观察组34例和对照组34例,分别给予内镜下组织胶注射或EVL治疗,术后随访1年。结果 观察组曲张静脉(EV)分级为F1、F2和F3分别为32.3%、50.0%和17.6%,Child-Pugh分级为B级和C级分别为76.5%和23.5%,与对照组比(分别为38.2%、41.2%和20.6%及76.5%和23.5%),无显著性差异(P>0.05);在急性期,对照组因失血性休克死亡3例;在生存者中,两组治疗前后肝功能指标变化无显著性差异(P>0.05);观察组止血成功率为100.0%,显著高于对照组的83.9%,而治疗次数、早期再出血率和迟发性再出血率分别为(1.4±0.6)次、2.9%和5.9%,显著少于或低于对照组【分别为(2.1±0.8)次、12.9%和22.6%,P<0.05】;术后,观察组胸骨后疼痛发生率为23.5%,显著高于对照组的6.5%,而两组吞咽困难、发热、自发性细菌性腹膜炎和因再出血死亡发生率无显著性差异(分别为8.8%、8.8%、5.9%和8.8%对0.0%、12.9%、9.7%和22.6%,均P>0.05)。结论 内镜下组织胶注射和EVL治疗乙型肝炎肝硬化并发EGVB患者均有良好的疗效,但各有优缺点,可根据各地条件和技术选择实施。

关键词: 肝硬化, 食管胃底静脉曲张破裂出血, 组织胶注射, 曲张静脉套扎术, 治疗

Abstract: Objective The purpose of this study was to investigate clinical efficacy of endoscopic tissue glue injection (ETG) and esophageal variceal ligation (EVL) in the treatment of patients with hepatitis B-induced liver cirrhosis complicated with esophageal variceal bleeding (EGVB). Methods 68 patients with hepatitis B-induced liver cirrhosis and complicated with EGVB were encountered in our hospital between September 2019 and December 2022, and were randomly divided into observation group (n=34) and control group (n=34), received ETG or EVL treatment, respectively, and all were followed-up for one year. The general data, perioperative indexes, blood biochemical indexes before and after treatment and the outcome were compared. Successful hemostasis is based on no active bleeding within 72 hours after operation. Early rebleeding is hematemesis or black stool again within 72 hours to 6 weeks after bleeding control, and delayed rebleeding was confirmed by gastroscopy with active bleeding 6 weeks after operation. Results There were no significant differences as respect to EV (F1, F2 and F3 in the observation group were 32.3%, 50.0% and 17.6%, and in the control were 38.2%, 41.2% and 20.6%, all P>0.05) or Child-Pugh class (class B and C were 76.5% and 23.5%, vs. 76.5% and 23.5%, P>0.05)between the two groups; three patients in the control group died of hemorrhagic shock at emergent stage; of survivals, there were no significant differences respect to liver function tests before and after operation between the two groups(P>0.05); successful hemostasis rate in the observation group was 100.0%, much higher than 83.9% in the control, while re-treatment times, early rebleeding and delayed rebleeding rates were (1.4±0.6)times, 2.9% and 5.9%, all significantly less or lower than [(2.1±0.8)times, 12.9% and 22.6%, respectively, P<0.05] in the control group; post-operationally, incidence of retrosternal pain in the observation was 23.5%, much higher than 6.5% in the control group, while there were no significant differences as respect to incidences of dysphagia, fever, spontaneous bacterial peritonitis and death owing to re-bleeding(8.8%, 8.8%, 5.9% and 8.8% vs. 0.0%, 12.9%, 9.7% and 22.6%, all P>0.05) between the two groups. Conclusion Endoscopic tissue glue injection and EVL in dealing with cirrhotics with urgent EGVB could obtain hemostasis and rescue patients life, and warrants further clinical investigation.

Key words: Liver cirrhosis, Esophagogastric variceal bleeding, Tissue glue injection, Esophageal variceal ligation, Therapy